A role for FOXO1 in BCR-ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Leukemia

Volumn 30, Issue 7, 2016, Pages 1493-1501

  Wagle, M ^a   Eiring, A M ^b   Wongchenko, M ^a   Lu, S ^a   Guan, Y ^a   Wang, Y ^a   Lackner, M ^a   Amler, L ^a   Hampton, G ^a   Deininger, M W ^b,c   O'Hare, T ^b,c   Yan, Y ^a  

^a GENENTECH INC   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENOSINE TRIPHOSPHATE; BCR ABL PROTEIN; BETA ARRESTIN 1; BETA CATENIN; CD34 ANTIGEN; COFILIN; DASATINIB; IMATINIB; INITIATION FACTOR 4G; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PICTILISIB; PONATINIB; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN KINASE C BETA; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; SMAD PROTEIN; TRANSCRIPTION FACTOR FKHR; 2-(1H-INDAZOL-4-YL)-6-(4-METHANESULFONYLPIPERAZIN-1-YLMETHYL)-4-MORPHOLIN-4-YLTHIENO(3,2-D)PYRIMIDINE; FOXO1 PROTEIN, HUMAN; INDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; SULFONAMIDE;

ARTICLE; CANCER RESISTANCE; CELL VIABILITY; CELLULAR DISTRIBUTION; CHRONIC MYELOID LEUKEMIA; COPY NUMBER VARIATION; ENZYME PHOSPHORYLATION; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEOMICS; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; DRUG TOLERANCE; K-562 CELL LINE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHYSIOLOGY; TUMOR CELL CULTURE;

APOPTOSIS; CELL PROLIFERATION; DASATINIB; DRUG RESISTANCE, NEOPLASM; DRUG TOLERANCE; FORKHEAD BOX PROTEIN O1; FUSION PROTEINS, BCR-ABL; HUMANS; IMATINIB MESYLATE; INDAZOLES; K562 CELLS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 84962110916     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.51     Document Type: Article

References (27)

1. O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer 2012; 12: 513-526.
2. Kantarjian HM, Larson RA, Guilhot F, O'Brien SG, Mone M, Rudoltz M, et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009; 115: 551-560.
3. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190-2196.
4. Soverini S, Colarossi S, Gnani A, Rosti G, Castagnetti F, Poerio A, et al. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia. Clin Cancer Res 2006; 12: 7374-7379.
5. Zabriskie MS, Eide CA, Tantravahi SK, Vellore NA, Estrada J, Nicolini FE, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell 2014; 26: 428-442.
6. Nambu T, Araki N, Nakagawa A, Kuniyasu A, Kawaguchi T, Hamada A, et al. Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells. Cancer Sci 2010; 101: 137-142.
7. Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncology 2011; 4: 6.
8. Eiring AM, Page BD, Kraft IL, Mason CC, Vellore NA, Resetca D, et al. Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. Leukemia 2015; 29: 586-597.
9. Traer E, MacKenzie R, Snead J, Agarwal A, Eiring AM, O'Hare T, et al. Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors. Leukemia 2012; 26: 1140-1143.
10. Burchert A, Wang Y, Cai D, von Bubnoff N, Paschka P, Muller-Brusselbach S, et al. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development. Leukemia 2005; 19: 1774-1782.
11. Tzivion G, Dobson M, Ramakrishnan G. FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta 2011; 1813: 1938-1945.
12. Tzivion G, Hay N. PI3K-AKT-FoxO axis in cancer and aging. Biochim Biophys Acta 2011; 1813: 1925.
13. Arden KC. Multiple roles of FOXO transcription factors in mammalian cells point to multiple roles in cancer. Exp Gerontol 2006; 41: 709-717.
14. Chen J, Gomes AR, Monteiro LJ, Wong SY, Wu LH, Ng TT, et al. Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer. PLoS One 2010; 5: e12293.
15. Kharas MG, Okabe R, Ganis JJ, Gozo M, Khandan T, Paktinat M, et al. Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice. Blood 2010; 115: 1406-1415.
16. Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y, et al. TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010; 463: 676-680.
17. Pellicano F, Scott MT, Helgason GV, Hopcroft LE, Allan EK, Aspinall-O'Dea M, et al. The antiproliferative activity of kinase inhibitors in chronic myeloid leukemia cells is mediated by FOXO transcription factors. Stem Cells 2014; 32: 2324-2337.
18. Yuan H, Wang Z, Gao C, Chen W, Huang Q, Yee JK, et al. BCR-ABL gene expression is required for its mutations in a novel KCL-22 cell culture model for acquired resistance of chronic myelogenous leukemia. J Biol Chem 2010; 285: 5085-5096.
19. O'Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16: 401-412.
20. Bourgon R, Lu S, Yan Y, Lackner MR, Wang W, Weigman V, et al. High-Throughput detection of clinically relevant mutations in archived tumor samples by multiplexed PCR and next-generation sequencing. Clin Cancer Res 2014; 20: 2080-2091.
21. Medina PP, Romero OA, Kohno T, Montuenga LM, Pio R, Yokota J, et al. Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat 2008; 29: 617-622.
22. Merel P, Hoang-Xuan K, Sanson M, Moreau-Aubry A, Bijlsma EK, Lazaro C, et al. Predominant occurrence of somatic mutations of the NF2 gene in meningiomas and schwannomas. Genes Chromosomes Cancer 1995; 13: 211-216.
23. Tzifi F, Economopoulou C, Gourgiotis D, Ardavanis A, Papageorgiou S, Scorilas A. The role of BCL2 family of apoptosis regulator proteins in acute and chronic leukemias. Adv Hematol 2012; 2012: 524308.
24. Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, et al. A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. Sci Transl Med 2014; 6: 252ra121.
25. Goto T, Takano M, Hirata J, Tsuda H. The involvement of FOXO1 in cytotoxic stress and drug-resistance induced by paclitaxel in ovarian cancers. Br J Cancer 2008; 98: 1068-1075.
26. Hui RC, Gomes AR, Constantinidou D, Costa JR, Karadedou CT, Fernandez de Mattos S, et al. The forkhead transcription factor FOXO3a increases phosphoinositide-3 kinase/Akt activity in drug-resistant leukemic cells through induction of PIK3CA expression. Mol Cell Biol 2008; 28: 5886-5898.
27. Burgering BM, Medema RH. Decisions on life and death: FOXO Forkhead transcription factors are in command when PKB/Akt is off duty. J Leuk Biol 2003; 73: 689-701.